Polymorphic variant Ser128Arg of E-selectin is associated with breast cancer risk and high grade tumors

Onkologie

Volumn 34, Issue 11, 2011, Pages 592-597

  Naidu, Rakesh ^a   Har, Yip C ^b,c   Taib, Nur A M ^b,c  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

^b Faculty of Medicine   (Malaysia)

^c UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Breast cancer; E Selectin; Polymorphism

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CARRIER; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALAYSIA; POLYMERASE CHAIN REACTION; PROTEIN POLYMORPHISM; PROTEIN VARIANT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; E-SELECTIN; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MALAYSIA; MIDDLE AGED; NEOPLASM GRADING; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 81855184554     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000334060     Document Type: Article

References (32)

1. Bevilacqua M, Nelson R: Selectins. J Clin Invest 1993;91:379-387. (Pubitemid 23064116)
2. Bevilacqua M, Pober J, Mendrick D, Cotran R, Gimbrone M: Identification of an inducible endo-thelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987;84:9238-9242.
3. Pigott R, Dillon LP, Hemingway IH, Gearing AJ: Soluble forms of E-selectin, ICAM-l and VCAM-l are present in the supernatants of cytokine-acti-vated cultured endothelial cells. Biochem Biophys Res Commun 1992;2:584-589.
4. Krause T, Turner G: Are selectins involved in metastasis? Clin Exp Metastasis 1999;17:83-92.
5. Nubel T, Dippold W, Kleinert H, Kaina B, Fritz G: Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. Faseb J 2004;18:140-142.
6. Laferriere J, Houle F, Huot J: Regulation of the metastatic process by E-selectin and stress-activated protein kinase-2/p38. Ann N Y Acad Sci 2002;973:562-572. (Pubitemid 36125071)
7. Laferriere J, Houle F, Taher MM, Valerie K, Huot J: Transendothelial migration of colon carcinoma cells requires expression of E-selectin by endothelial cells and activation of stress-activated protein kinase-2 (SAPK2/p38) in the tumor cells. J Biol Chem 2001;276:33762-33772.
8. Chambers AF, Groom AC, MacDonald IC: Metastasis: dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-572. (Pubitemid 37328923)
9. Biancone L, Arak iM, Araki K, Vassalli P, Stamenkovic I: Redirection of tumor metastasis by expression of E-selectin in vivo. J Exp Med 1996;83:581-587. (Pubitemid 26060792)
10. Fox SB, Turner GD, Gatter KC, Harris AL: The increased expression of adhesion molecules ICAM-3, E-and P-selectins on breast cancer endothelium. J Pathol 1995;177:369-378.
11. Renkonen J, Paavonen T, Renkonen R: Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma Int J Cancer 1997;74:296-300. (Pubitemid 27321799)
12. Nguyen M, Corless CL, Kraling BM, Tran C, Atha T, Bischoff J, Barsky SH: Vascular expression of E-selectin is increased in estrogen-receptor-negative breast cancer: a role for tumor-cell-secreted interleukin-1 alpha. Am J Pathol 1997; 150:1307-1314. (Pubitemid 27152649)
13. Hebbar M, Revillion F, Louchez M, Fournier C, Bonneterre J, Peyrat JP: Prognostic value of circulating soluble E-selectin in node-negative breast cancer patients. Clin Cancer Res 1999;5:1427-1433. (Pubitemid 29282948)
14. Hebbar M, Reaposvillion F, Louchez M, Vilain M, Fournier C, Bonneterre J, Peyrat JP: The relationship between concentrations of circulating soluble E-selectin and clinical, biological, and pathological features in patients with breast cancer. Clin Cancer Res 1998;4:373-380. (Pubitemid 28122752)
15. Rao RM, Clarke JL, Ortlepp S, Robinson M, Landis R, Haskard D: The S128R polymorphism of E-selectin mediates neuraminidase-resistant tethering of myeloid cells under shear flow. Eur J Immunol 2002;32:251-260. (Pubitemid 34092842)
16. Rao RM, Haskard DO, Landis RC: Enhanced recruitment of Th2 and CLA-negative lymphocytes by the S128R polymorphism of E-selectin. J Immunol 2002;169:5860-5865. (Pubitemid 35291690)
17. Yoshida M, Takano Y, Sasaoka T, Izumi T, Kimura A: E-selectin polymorphism associated with myocardial infarction causes enhanced leukocyte-endothelial interactions under flow conditions. Arterioscler Thromb Vasc Biol 2003;23:783-788. (Pubitemid 36566166)
18. Alessandro R, Seidita G, Flugy AM, Damiani F, Russo A, Corrado C, Colomba P, Gulotti L, Buettner R, Bruno L, De Leo G: Role of S128R polymorphism of E-selectin in colon metastasis formation. Int J Cancer 2007;121:528-535. (Pubitemid 46986485)
19. Hebbar M, Adenis A, Revillion F, Duhamel A, Romano O, Truant S, Libersa C, Giraud C, Triboulet JP, Pruvot FR, Peyrat JP: E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer. Eur J Cancer 2009;45:1871-1876.
20. Panoussopoulos GS, Theodoropoulos G, Michalopoulos NV, Gazouli M, Flessas J, Taka S, Stamopoulos P, Manouras A, Zografos GC: Analysis of E-selectin S128R gene polymorphism in pancreatic cancer. J Surg Oncol 2010;102:604-607.
21. Lim GCC, Halimah Y: Second Report of the National Cancer Registry. Cancer Incidence in Malaysia 2003. National Cancer Registry. Kuala Lumpur, 2004.
22. Naidu R, Har YC, Taib NA: Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development. Oncol Res 2009;18:65-71.
23. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer I. Histo-pathology 1991;19:403-410.
24. Bloom HI, Richardson WW: Histological grading and prognosis. Br J Cancer 1957;11:359-377.
25. American Joint Committee on Cancer: AJCC Cancer Staging Manual, 6th ed. Springer, New York, 2002, pp. 171-180.
26. Singletary E, Allred C, Ashley P, Bassett L, Berry D, Bland K, Borgen C, Edge B, Hayes D, Hughes L, Hutter R, Morrow M, Page D, Recht A, Theriault R, Thor A, Weaver H, Wieland S, Greene F: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20:3628-3636. (Pubitemid 34983222)
27. Naidu R, Har YC, Taib NA: P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer. J Exp Clin Cancer Res 2007;26:133-140. (Pubitemid 46650054)
28. Wenzel K, Felix S, Kleber FX, Brachold R, Menke T, Schattke S, Schulte KL, Glaser C, Rohde K, Baumann G, Speer A: E-selectin polymorphism and atherosclerosis: an association study. Hum Mol Genet 1994;3:1935-1937. (Pubitemid 24341367)
29. Li Y, Wei YS, Wang M, Zhang PA, Jiang XJ, Huang CX: Association between the Ser128Arg variant of the E-selectin and risk of coronary artery disease in the central China. Int J Cardiol 2005;103:33-36. (Pubitemid 41074601)
30. Tozeren A, Kleinman HK, Grant DS, Morales D, Mercurio AM, Byers SW: Eselectin-mediated dynamic interactions of breast-and colon-cancer cells with endothelial-cell monolayers. Int J Cancer 1995;60:426-431.
31. Moss MA, Zimmer S, Anderson KW: Role of metastatic potential in the adhesion of human breast cancer cells to endothelial monolayers. Anticancer Res 2000;20:1425-1433. (Pubitemid 30628146)
32. Sheen-Chen S, Eng H, Huang C, Chen W: Serum levels of soluble E-selectin in women with breast cancer. Br J Surg 2004;91:1578-1581. (Pubitemid 39619920)